Table 1 Main characteristics of patients at immunotherapy (n = 110)

Age at metastasis, years, median [range]

60 [31–92]

Sex male

60 (55)

Basal LDH^a

    Normal

60 (54)

    Increased

46 (42)

N of metastatic sites^b

169 (62.1)

     < 3

73 (66)

     ≥ 3

36 (33)

Site of melanoma

Cutaneous

87 (79)

    Mucosal

3 (3)

    Ocular

3 (5)

    unknown

14 (13)

Prior Adjuvant therapy

6 (5)

Prior therapy for metastatic disease

47 (43)

ECOG PS^c

    0

57 (52)

    1

42 (38)

    2

9 (8)

Stage at metastatic disease

    M1a

30 (27)

    M1b

19 (17)

    M1c

45 (41)

    M1d

16 (15)

Therapy

Anti-PD-1

106 (96)

Anti-PD-1 plus Anti-CTLA-4

4 (4)